A fiber-coated membrane carrying a recombinant viral vector, its preparation method and application

By preparing core-shell structured fiber coatings through coaxial electrospinning, the targeting and release instability issues in viral vector delivery methods were resolved, improving the transduction efficiency and gene editing effect of viral vectors and reducing side effects.

CN116832014BActive Publication Date: 2026-11-10SHANGHAI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310790529.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-06-29
Publication Date
2026-11-10
Estimated Expiration
2043-06-29

AI Technical Summary

Technical Problem

Existing viral vector delivery methods suffer from problems such as poor targeting, antibody production, and immune response, resulting in poor efficacy of gene therapy. Furthermore, the viral activity is low and drug release is unstable during electrospinning.

Method used

A core-shell structured fiber membrane was prepared using coaxial electrospinning technology. The inner layer was a recombinant viral vector, and the outer layer was a biodegradable polymer. The fiber membrane carrying the recombinant viral vector was formed by freeze-drying, ensuring viral activity and enabling controlled release.

Benefits of technology

It improves the transduction efficiency and gene editing effect of viral vectors, avoids explosive release of viral vectors, maintains viral activity, and reduces systemic side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116832014B_ABST
    Figure CN116832014B_ABST
Patent Text Reader

Abstract

This invention belongs to the field of biomedical technology, specifically relating to a fiber membrane carrying a recombinant viral vector, its preparation method, and its application. This invention utilizes coaxial electrospinning technology to prepare a fiber membrane carrying a recombinant viral vector, resulting in a fiber membrane with a core-shell structure. A biodegradable polymer is used as the raw material for the shell layer, enabling rapid degradation and controlled release of the recombinant viral vector. Furthermore, the shell layer acts as a protective layer, maintaining the activity of the recombinant viral vector within the core structure, thereby enhancing the transduction efficiency and gene editing effect of the recombinant viral vector in cells. Moreover, the shell layer of the fiber membrane carrying the recombinant viral vector, prepared using coaxial electrospinning technology, encapsulates the core layer to form core-shell structured fibers, ensuring the recombinant viral vector encapsulated within the core layer is protected throughout the process, further maintaining the activity of the recombinant viral vector.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedical technology, specifically relating to a fiber membrane for carrying recombinant viral vectors, its preparation method, and its application. Background Technology

[0002] With the gradual maturation of technologies such as DNA recombination and gene cloning, and the continuous development of gene therapy, new options have been brought to the treatment of various diseases, including tumors, hereditary diseases, and autoimmune diseases. In gene therapy, gene delivery systems are the most critical technology. Gene delivery vectors are divided into two main categories: viral vectors and non-viral vectors. Viral vectors have advantages such as high transduction efficiency, broad host range, simple genome structure, and ease of modification and preparation; however, they also suffer from poor targeting and limited controllability. Therefore, how to deliver viral vectors in a controllable manner has become a research challenge.

[0003] Currently, the commonly used delivery methods for viral vectors are site-directed injection and intravenous injection. However, these methods have the following drawbacks: 1) Poor targeting: When the injected viral vector transduces host cells, it may transduce to other cells, leading to significant infection in other sites and causing adverse reactions; 2) Prone to antibody production: This reduces the effectiveness of repeated administration and greatly increases the risk of off-target effects; 3) Prone to immune responses: When the injected viral dose is high, an immune response may occur, interfering with the interaction between the viral vector and cells and severely hindering the gene therapy process. Therefore, how to deliver gene-carrying viral vectors has become a key research focus in clinical medicine.

[0004] Nanoparticle drug carriers have attracted attention in the biomedical field due to their advantages such as targeted drug delivery close to the lesion site, reduced drug dosage, and lower drug usage frequency. Nanofiber membranes are one type of drug carrier, and electrospinning is a commonly used technique for preparing nanofiber membranes. To ensure effective drug delivery, the prepared nanofiber membranes should not only enable targeted drug delivery but also allow for controlled drug release. Currently, there are studies using electrospinning to prepare nanofiber membranes as viral vectors for targeted drug delivery. However, the electrospinning process suffers from problems such as low viral activity, low transduction efficiency to cells, and explosive drug release due to high pressure and extrusion. Furthermore, viruses are highly sensitive to environmental temperature; storage at room temperature or during shaping significantly reduces their activity. Summary of the Invention

[0005] The purpose of this invention is to provide a fiber membrane carrying a recombinant viral vector, its preparation method, and its application. The fiber membrane carrying the recombinant viral vector prepared by the method can enable the controlled release of gene drugs and efficient transduction in host cells while maintaining the activity of the recombinant viral vector.

[0006] This invention provides a method for preparing a fiber-coated membrane carrying a recombinant viral vector, comprising the following steps:

[0007] The inner spinning solution and the outer spinning solution are coaxially electrospun to obtain a coaxial electrospun core-shell fiber membrane. The inner spinning solution is a recombinant virus vector solution, and the outer spinning solution is a biodegradable polymer solution.

[0008] The coaxial electrospun core-shell fiber membrane was freeze-dried to obtain the fiber membrane carrying the recombinant virus vector.

[0009] Preferably, the biodegradable polymer solution comprises a biodegradable polymer and a first solvent; the first solvent comprises at least one of chloroform, dichloromethane, and N,N-dimethylformamide.

[0010] The biodegradable polymer has a mass fraction of 5-20% in the biodegradable polymer solution.

[0011] Preferably, the biodegradable polymer includes at least one of silk fibroin, polylactic acid, chitosan, sodium alginate, gelatin, polycaprolactone, polyethylene oxide, cellulose acetate, and polylactic-co-hydroxyacetic acid copolymer.

[0012] Preferably, the recombinant viral vector solution comprises a recombinant viral vector and a second solvent; the second solvent comprises at least one of phosphate buffer solution, chloroform, and dichloromethane.

[0013] The initial viral vector of the recombinant viral vector includes an adeno-associated virus vector; the content of the recombinant viral vector in the recombinant viral vector solution is (1-3)×10 based on the number of particles of the initial viral vector. 9 Particles / μL.

[0014] Preferably, the ambient temperature for the coaxial electrospinning is 0–8°C, and the relative humidity is 30–55%.

[0015] Preferably, the coaxial nozzle of the coaxial electrospinning includes an inner needle and an outer needle; the inner diameter of the inner needle is 0.15-0.55 mm and the outer diameter is 0.6-0.8 mm; the inner diameter of the outer needle is 0.85-1.3 mm and the outer diameter is 1.25-1.75 mm.

[0016] Preferably, the spinning flow rate of the outer layer solution is 0.1–0.4 mL / h; and the spinning flow rate of the inner layer solution is 0.05–0.3 mL / h.

[0017] Preferably, the voltage of the coaxial electrospinning is 9-22kV; the distance from the coaxial nozzle to the receiving device is 12-20cm; and the rotational speed of the receiving device is 500-700r / min.

[0018] The present invention also provides a fiber membrane for preparing a recombinant viral vector by the preparation method described above. The fibers forming the fiber membrane for the recombinant viral vector have a core-shell structure, with the shell layer being a biodegradable polymer and the core layer being a recombinant viral vector. The thickness of the fiber membrane for the recombinant viral vector is 75–125 μm, and the diameter of the fiber filaments is 0.3–1 μm.

[0019] The present invention also provides the application of the fiber coating of the recombinant viral vector described in the above technical solution in the preparation of gene therapy devices.

[0020] Beneficial effects:

[0021] This invention provides a method for preparing a fiber coating carrying a recombinant viral vector, comprising the following steps: coaxial electrospinning an inner spinning solution and an outer spinning solution to obtain coaxial electrospun core-shell fibers, wherein the inner spinning solution is a recombinant viral vector solution and the outer spinning solution is a biodegradable polymer solution; and freeze-drying the coaxial electrospun core-shell fibers to obtain the fiber coating carrying the recombinant viral vector.

[0022] This invention utilizes coaxial electrospinning technology to prepare a fiber membrane carrying a recombinant viral vector, resulting in a fiber membrane with a core-shell structure. A biodegradable polymer is used as the raw material for the shell layer, allowing it to degrade rapidly and gradually release the recombinant viral vector encapsulated in the core layer. This avoids explosive release of the recombinant viral vector, ensuring stable release and achieving controlled release. Furthermore, the shell layer acts as a protective layer, maintaining the activity of the recombinant viral vector within the core structure, thereby enhancing the transduction efficiency and gene editing effect of the recombinant viral vector in cells. Moreover, the coaxial electrospinning technology-prepared fiber membrane encapsulates the core layer, forming a core-shell structure fiber filament. This ensures the recombinant viral vector encapsulated in the core layer is protected throughout the process, and the recombinant viral vector is evenly distributed within the core-shell fiber matrix, unaffected by organic solvent evaporation, further maintaining the activity of the recombinant viral vector. Attached Figure Description

[0023] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the accompanying drawings used in the embodiments will be briefly described below.

[0024] Figure 1 This is a schematic diagram of the preparation process of the fiber coating carrying the recombinant viral vector in Example 1;

[0025] Figure 2 This is a schematic diagram of the structure of the fiber-coated recombinant virus vector prepared in Example 1;

[0026] Figure 3 This is a scanning electron microscope image of the fiber-coated recombinant virus vector prepared in Example 1;

[0027] Figure 4 The in vitro release curves of the fiber coatings prepared in Example 1 and Comparative Example 1 are shown.

[0028] Figure 5 The cell transduction efficiency of the fiber-coated membranes prepared in Example 1 and Comparative Examples 1-2 is shown in the figure.

[0029] Figure 6 This is a schematic diagram of the fiber-coated targeted drug delivery system using a recombinant viral vector prepared in this invention.

[0030] Figure 7 This is a schematic diagram of the recombinant viral vector transduction of host cells and gene editing process in this invention. Detailed Implementation

[0031] This invention provides a method for preparing a fiber-coated membrane carrying a recombinant viral vector, comprising the following steps:

[0032] Coaxial electrospinning of inner and outer spinning solutions yields coaxial electrospun core-shell fibers. The inner spinning solution is a recombinant virus vector solution, and the outer spinning solution is a biodegradable polymer solution.

[0033] The coaxial electrospun core-shell fibers were freeze-dried to obtain the fiber coating carrying the recombinant virus vector.

[0034] The biodegradable polymer solution of the present invention preferably includes a biodegradable polymer and a first solvent. Specifically, the biodegradable polymer is dissolved in the first solvent to obtain the biodegradable polymer solution. The first solvent includes at least one of chloroform, dichloromethane and N,N-dimethylformamide.

[0035] In this invention, the biodegradable polymer is preferably dissolved in a first solvent to obtain a biodegradable polymer solution. The first solvent preferably includes at least one of chloroform, dichloromethane, and N,N-dimethylformamide (DMF), more preferably two of chloroform, dichloromethane, and N,N-dimethylformamide (DMF), and even more preferably chloroform and N,N-dimethylformamide (DMF); the volume ratio of chloroform to N,N-dimethylformamide (DMF) is preferably (1-9):(1-3), and more preferably 9:1.

[0036] The biodegradable polymer of the present invention preferably includes at least one of silk fibroin (SF), polylactic acid (PLA), chitosan (CS), sodium alginate (SA), gelatin (Gel), polycaprolactone (PCL), polyethylene oxide (PEO), cellulose acetate (CA), and polylactic-co-glycolic acid copolymer (PLGA), more preferably including two of silk fibroin (SF), polylactic acid (PLA), chitosan (CS), sodium alginate (SA), gelatin (Gel), polycaprolactone (PCL), polyethylene oxide (PEO), cellulose acetate (CA), and polylactic-co-glycolic acid copolymer (PLGA), and more preferably polyethylene oxide (PEO) and polycaprolactone (PCL). When the biodegradable polymer preferably comprises two substances, the mass ratio between the two substances is preferably (1-12):(1-5). For example, when the two substances are polyethylene oxide (PEO) and polycaprolactone (PCL), the mass ratio of PEO to PCL is preferably (1-12):1, more preferably (6-9):1. The mass fraction of the biodegradable polymer in the biodegradable polymer solution is preferably 5-20%, more preferably 10-15%, and more preferably 11%.

[0037] In this invention, the biodegradable polymer is preferably dissolved in the first solvent by a first stirring motion. The stirring speed is preferably 450–750 r / min, more preferably 600 r / min; the stirring time is preferably 2–5 h, more preferably 3–4 h; and the stirring temperature is preferably 18–36 °C, more preferably 26 °C. Preferably, the first stirring is performed using a magnetic stirrer. The source and model of the magnetic stirrer are not particularly limited; any conventional magnetic stirrer in the art can be used.

[0038] The recombinant viral vector solution of the present invention preferably includes a recombinant viral vector and a second solvent. Specifically, the recombinant viral vector is uniformly dispersed in the second solvent to obtain the recombinant viral vector solution. The second solvent includes at least one of phosphate buffer solution, chloroform and dichloromethane.

[0039] In this invention, the recombinant viral vector is preferably uniformly dispersed in a second solvent to obtain a recombinant viral vector solution. The second solvent preferably includes at least one of phosphate buffer solution, chloroform, and dichloromethane, more preferably phosphate buffer solution, chloroform, or dichloromethane, and even more preferably phosphate buffer solution; the pH value of the phosphate buffer solution is preferably 7.4. The initial vector of the recombinant viral vector of this invention preferably includes an adeno-associated virus vector; the content of the recombinant viral vector in the recombinant viral vector solution is preferably (1-3) × 10⁻⁶ particles, based on the number of particles of the initial viral vector. 9 Particles / μL, more preferably 2.5 × 10⁻⁶.9 Particles / μL. This invention uses recombinant viral vectors as gene vectors, which have advantages such as high transduction efficiency, high safety, low immunogenicity, and long in vivo expression time of exogenous genes. This invention does not specifically limit the type of target gene in the recombinant viral vector; it can be selected conventionally according to the preparation purpose. This invention does not specifically limit the preparation method of the recombinant viral vector; conventional preparation methods in the art can be used.

[0040] In this invention, the recombinant viral vector is preferably uniformly dispersed in a second solvent by a second stirring motion. The stirring speed is preferably 200–300 r / min, more preferably 250 r / min; the stirring time is preferably 15–45 min, more preferably 30 min; and the stirring temperature is preferably 0–7°C, more preferably 4°C. Preferably, the second stirring is performed using a magnetic stirrer. The source and model of the magnetic stirrer are not particularly limited; any conventional magnetic stirrer in the art can be used.

[0041] After obtaining the biodegradable polymer solution and the recombinant viral vector solution, the present invention uses the recombinant viral vector solution as the inner layer liquid and the biodegradable polymer solution as the outer layer liquid for coaxial electrospinning to obtain coaxial electrospun core-shell fibers. The coaxial nozzle of the coaxial electrospinning of the present invention includes an inner needle and an outer needle. The inner diameter of the inner needle is preferably 0.15–0.55 mm, more preferably 0.35–0.45 mm; the outer diameter is preferably 0.6–0.8 mm, more preferably 0.65–0.75 mm; and the inner needle is preferably numbered 22G. The inner diameter of the outer needle is preferably 0.85–1.3 mm, more preferably 0.95–1.1 mm; the outer diameter is preferably 1.25–1.75 mm, more preferably 1.4–1.6 mm; and the outer needle is preferably numbered 17G. By controlling the inner diameter, outer diameter, and numbering of the inner and outer needles, it is possible to avoid clogging of the coaxial nozzle during the preparation process, prevent the formation of beads on the coaxial electrospun fibers, and control the diameter of the coaxial electrospun fibers.

[0042] The spinning flow rate of the outer layer solution in this invention is preferably 0.1–0.4 mL / h, more preferably 0.2–0.3 mL / h; the spinning flow rate of the inner layer solution is preferably 0.05–0.3 mL / h, more preferably 0.1–0.2 mL / h. By controlling the flow rates of the outer and inner layer solutions, the stability of the needle droplets and the diameter of the fibers can be controlled, as well as the formation of bead-like fibers can be avoided.

[0043] The voltage for coaxial electrospinning described in this invention is preferably 9–22 kV, more preferably 12–19 kV. The distance from the coaxial nozzle to the receiving device is preferably 12–20 cm, more preferably 14–18 cm; the rotational speed of the receiving device is preferably 500–700 r / min, more preferably 560 r / min.

[0044] In the preparation process described above, the preferred ambient temperature is 0–8°C, more preferably 4°C; the preferred relative humidity is 30–55%, more preferably 45%. The preparation temperature described in this invention can effectively maintain the activity of the recombinant viral vector and avoid inactivation of the recombinant viral vector due to excessively high temperatures.

[0045] After obtaining the coaxial electrospun core-shell fiber, the present invention freeze-dries the coaxial electrospun core-shell fiber to obtain the fiber coating carrying the recombinant viral vector. The pre-freezing temperature of the freeze-drying process is preferably -40 to -30°C, more preferably -35°C; the time is preferably 5 to 15 hours, more preferably 12 hours; the drying temperature is preferably 20 to 35°C, more preferably 28°C; the drying time is preferably 16 to 32 hours, more preferably 24 hours; and the vacuum degree is preferably 1 to 3 Pa, more preferably 2 Pa. The freeze-drying process of the present invention can prevent the dissolution of the recombinant viral vector solution in the core layer of the prepared core-shell fiber, while allowing the small amount of solvent remaining on the fiber surface to fully evaporate.

[0046] The present invention also provides a fiber membrane for preparing a recombinant viral vector by the preparation method described above. The fiber membrane for preparing the recombinant viral vector has a core-shell structure, the shell layer is a biodegradable polymer layer, and the core layer is a recombinant viral vector. The thickness of the fiber membrane for preparing the recombinant viral vector is 75-125 μm, and the diameter of the fiber filaments is 0.3-1 μm.

[0047] The thickness of the fiber coating of the recombinant viral vector of the present invention is preferably 100 μm, the diameter of the fiber filaments is preferably 0.55 μm, and the surface of the fiber filaments is smooth and uniformly distributed.

[0048] This invention utilizes coaxial electrospinning technology to prepare a fiber membrane carrying a recombinant viral vector, resulting in a fiber membrane with a core-shell structure. A biodegradable polymer is used as the raw material for the shell layer, enabling it to degrade rapidly and gradually release the recombinant viral vector loaded in the core layer. This avoids explosive release of the recombinant viral vector, ensuring a more stable release and achieving controlled release. Furthermore, the shell layer acts as a protective layer, maintaining the activity of the recombinant viral vector in the core structure, thereby enhancing the transduction efficiency and gene editing effect of the recombinant viral vector in cells.

[0049] In the process of preparing the fiber coating of a core-shell recombinant viral vector, this invention employs a coaxial nozzle composed of two needles of different diameters arranged coaxially. The outer needle corresponds to a biodegradable shell structure, which serves as a protective layer to maintain the activity of the recombinant viral vector while also acting as a controlled-release layer to achieve targeted release of the vector, thereby improving the transduction efficiency and gene editing effect of the recombinant viral vector in cells. The inner needle corresponds to the core structure, which is composed of a recombinant viral vector solution. Under a strong electric field, the organic solvent evaporates rapidly, and the shell layer encapsulates the core layer to form core-shell fibers. The recombinant virus loaded in the core layer is protected throughout the process and is uniformly distributed within the core-shell fiber matrix, unaffected by the evaporation of the organic solvent, thus maintaining the activity of the recombinant viral vector.

[0050] Compared to commonly used injection-delivered recombinant viral vectors, using a fiber-coated recombinant viral vector allows the release site to be as close as possible to the pathogen, improving host cell transduction efficiency while avoiding systemic side effects and exhibiting better stability and cell transduction efficiency. Simultaneously, it avoids the impact of compression during injection on viral activity.

[0051] Based on the above advantages, the present invention also provides the application of the fiber coating carrying the recombinant viral vector described in the above technical solution in the preparation of gene therapy devices. The gene therapy drug of the present invention preferably includes a vascular stent coating.

[0052] When applying the fiber-coated membrane carrying the recombinant viral vector described in this invention, the location of the aortic dissection rupture is first determined. Then, a small incision is made in the groin area, and a guidewire and catheter are inserted into the aorta. The fiber-coated membrane carrying the recombinant viral vector is then delivered to the rupture site via a delivery device. After the fiber-coated membrane is in place, it is locally expanded to adhere to the aortic wall, thereby achieving targeted drug delivery to the lesion site. Figure 6 As shown.

[0053] In this invention, the working principle of the fiber coating carrying the recombinant viral vector (e.g.) Figure 7 As shown, when the fibrous membrane carrying the recombinant viral vector seals the aortic dissection rupture, the recombinant viral vector carried in the fibrous membrane is gradually released. The released recombinant viral vector is recognized by receptors on the surface of the host cell and enters the host cell through endocytosis. Secondly, after accumulating around the cell nucleus, it enters the nucleus and undergoes proteolysis and decoagulation by the proteasome within the cell, thereby releasing the gene carried by the recombinant viral vector. Finally, through gene transcription and output, it is used for translation and expression of therapeutic transgenes, achieving the effect of gene editing.

[0054] To further illustrate the present invention, the technical solutions provided by the present invention will be described in detail below with reference to the accompanying drawings and embodiments, but these should not be construed as limiting the scope of protection of the present invention.

[0055] Example 1

[0056] A method for preparing a fiber-coated membrane carrying a recombinant viral vector, the specific steps of which are as follows, and the preparation process is as follows: Figure 1 As shown:

[0057] Step (1) Preparation of shell-degradable polymer solution: Dissolve 0.99g of PEO powder (purity 98%) and 0.11g of PCL solid particles (purity 98%) in a mixed solution of 9mL chloroform and 1mL DMF. Stir at room temperature (26℃) for 3h using a magnetic stirrer at a stirring speed of 600r / min to ensure uniform mixing of the polymer solution. During stirring, seal the beaker with double-layer plastic wrap to slow down the evaporation rate of the solvent. Finally, obtain an 11wt% PEO / PCL (9:1) polymer solution as the shell solution for coaxial electrospinning.

[0058] Step (2) Preparation of the core layer AAV virus vector solution: 1.15 × 10 13 AAV virus particles were dissolved in 5 mL of PBS solution (pH 7.4) and stirred with a magnetic stirrer at 200 rpm for 20 min at 4 °C, yielding a concentration of 2.3 × 10⁻⁶. 9 AAV virus particles per microliter of coaxial electrospun core layer solution; wherein the preparation method of AAV virus particles is as follows:

[0059]

[0060] Step (3) Preparation of the fiber coating carrying the AAV virus vector: Coaxial electrospinning was performed using the shell-layer biodegradable polymer solution and the core-layer AAV virus vector solution prepared in steps (1) and (2). First, the solutions were loaded into 10 mL syringes, and then air bubbles were expelled from the syringes to avoid affecting the electrospinning process. After the air bubbles were expelled, the syringes were connected to the corresponding channels of the coaxial electrospinning nozzles. The coaxial electrospinning nozzles used consisted of two needles of different diameters arranged coaxially, corresponding to the core-layer AAV virus vector solution and the shell-layer biodegradable polymer solution, respectively. Finally, after 8 hours of coaxial electrospinning, a fiber coating with a thickness of 110 μm was obtained. The coaxial electrospinning parameters used were as follows: the outer needle of the coaxial electrospinning nozzle was numbered 17G (inner diameter: 1.01 mm; outer diameter: 1.49 mm); the inner needle was numbered 22G (inner diameter: 0.41 mm; outer diameter: 0.72 mm); the flow rate of the shell polymer solution was 0.30 mL / h; the flow rate of the core AAV virus vector solution was 0.15 mL / h; the applied voltage was 20 kV; the distance from the nozzle to the receiving device was 18 cm; the rotation speed of the receiving device was 600 r / min; the ambient temperature during the coaxial electrospinning process was 4℃; and the relative humidity was 55%.

[0061] Step (4) The fiber membrane prepared in step (3) is subjected to freeze-drying for 24 hours: the pre-freezing temperature is -35℃, the drying temperature is 28℃, and the vacuum degree is 2Pa. After freeze-drying, it is completely peeled off from the collection device to obtain the fiber membrane carrying the AAV virus vector, the structure of which is shown in the figure below. Figure 2 As shown, scanning electron microscopy revealed that the surface of the fiber-coated filaments was smooth and uniformly distributed. Figure 3 As shown. The fiber diameter was measured using NanoMeasurer software, and the average fiber diameter was found to be 0.56 μm; the thickness of the fiber membrane was measured using a micrometer, and the thickness of the fiber membrane was found to be 110 μm.

[0062] Comparative Example 1

[0063] A method for preparing a fiber-coated recombinant viral vector with a non-nuclear-shell structure, comprising the following steps:

[0064] Steps (1) to (2) are the same as in Example 1.

[0065] Step (3) Preparation of AAV virus vector blend solution: The solutions prepared in steps (1) and (2) are placed in a sealed container at a ratio of 1:1 (v / v) and stirred at 200 r / min for 1 h at 4 °C with a magnetic stirrer to make the AAV virus vector uniformly distributed in the polymer solution, and finally the AAV virus vector blend solution is obtained.

[0066] Step (4) Preparation of the fiber membrane carrying the AAV virus vector: The AAV virus vector blend solution prepared in step (3) was loaded into a 10 mL syringe. After the air bubbles were eliminated, the syringe was connected to the electrospinning nozzle and electrospinned for 8 hours to obtain a virus-carrying fiber membrane with a thickness of 120 μm. The electrospinning parameters used were as follows: the electrospinning nozzle was numbered 22G (inner diameter: 0.41 mm; outer diameter: 0.72 mm), the flow rate of the blend solution was 0.5 mL / h, the applied voltage was 16 kV, the distance from the nozzle to the receiving device was 16 cm, the rotation speed of the receiving device was 600 r / min, the ambient temperature was 4 °C, and the relative humidity was 55%.

[0067] Comparative Example 2

[0068] A method for preparing a core-shell structured fiber membrane carrying plasmid DNA, comprising the following steps:

[0069] Step (1) is the same as in Example 1.

[0070] Step (2) Preparation of core plasmid DNA solution: Add 5 μL of plasmid DNA solution (5.82 μg / μL) to 2 mL of PBS solution (pH 7.4), and stir with a magnetic stirrer for 5 min at room temperature (26℃) at a stirring speed of 450 r / min to obtain core plasmid DNA solution.

[0071] The preparation steps for the nuclear plasmid are as follows:

[0072] First, the human whole genome was amplified by nested polymerase chain reaction (PCR) to obtain the nuclear CMV-EGFP-WPRE gene fragment with the same nucleotide sequence as above. Then, the double-digested target gene fragment was ligated with the AAV-1 expression vector using homologous recombination to obtain the nuclear plasmid AAV-1.

[0073] Step (3) Preparation of plasmid DNA fiber membrane: The solutions prepared in steps (1) and (2) are respectively loaded into 5 mL syringes. After the air bubbles are eliminated, the syringes are connected to the corresponding channels of the coaxial electrospinning nozzles, corresponding to the core plasmid DNA solution and the shell polymer solution, respectively. Finally, after 8 hours of coaxial electrospinning, a fiber membrane with a thickness of 125 μm carrying plasmid DNA is obtained. The coaxial electrospinning parameters used were as follows: the outer needle of the coaxial electrospinning nozzle was numbered 17G (inner diameter: 1.01 mm; outer diameter: 1.49 mm); the inner needle was numbered 22G (inner diameter: 0.41 mm; outer diameter: 0.72 mm); the flow rate of the shell polymer solution was 0.45 mL / h; the flow rate of the core plasmid DNA solution was 0.2 mL / h; the applied voltage was 21 kV; the distance from the nozzle to the receiving device was 17 cm; the rotation speed of the receiving device was 600 r / min; the ambient temperature during the coaxial electrospinning process was 26℃; and the relative humidity was 50%.

[0074] Step (4) The vascular scaffold membrane carrying plasmid DNA was freeze-dried for 24 hours: the pre-freezing temperature was -35℃, the drying temperature was 28℃, and the vacuum degree was 2Pa. After the freeze-drying was completed, it was completely peeled off from the collection device.

[0075] Test Example 1

[0076] The fiber membranes carrying recombinant viral vectors prepared in Example 1 and Comparative Examples 1-2 were cut into 1cm × 1cm samples for the following tests: AAV virus activity and in vitro release tests were performed on the fiber membranes prepared in Example 1 and Comparative Examples 1-2; cell transduction tests were performed on the fiber membranes prepared in Example 1 and Comparative Examples 1-2.

[0077] AAV virus activity assay: First use OD 260 The number of AAV virus particles was determined using a specific method. The fiber-coated samples prepared in Example 1 and Comparative Example 1 were placed in 2 mL of DMEM medium (containing 10% FBS and 2 mM glutamine), and shaken vigorously at room temperature for 2 hours. Proteinase K lysis buffer was then added, and the absorbance at 260 nm was measured using a UV spectrophotometer. The number of AAV virus particles was calculated using the formula: AAV virus particles / mL = OD0 260 ×Dilution factor×10 12 .

[0078] Then use TCID 50 Methods for detecting AAV virus activity: Samples were diluted according to the number of AAV virus particles. 100 μL of each serial dilution buffer was added to each well of a 96-well plate, with each dilution repeated in 8 wells. Eight wells were reserved as a blank control group. Then, 100 μL of 293 cell suspension was added, with a cell density of 5.0 × 10⁻⁶ cells / well.5 Cells / mL. Then, it was incubated at 37℃ with 5% CO2. The AAV virus titer was calculated using the Karber method, with the formula: lgTCID. 50 =LD(S-0.5). Where L is the logarithm of the highest dilution; D is the difference between the logarithms of dilutions; and S is the sum of the positive well ratios. The percentage of AAV viral activity is determined by TCID. 50 The calculated data were divided by the control group to estimate the activity. The results of the AAV virus activity assay are shown in Table 1.

[0079] Table 1. Results of AAV virus activity assays on fiber-coated recombinant virus vectors prepared in Example 1 and Comparative Example 1.

[0080] Example Example 1 Comparative Example 1 AAV viral activity (%) 94 33

[0081] Table 1 shows that the AAV virus activity in the fiber membrane containing the recombinant virus vector prepared in Example 1 is high, reaching up to 94%, which is significantly higher than the 33% AAV virus activity in Comparative Example 1.

[0082] In vitro release assay: The fiber-coated samples containing the recombinant viral vector prepared in Example 1 and Comparative Example 1 were placed in 12-well culture plates and then immersed in 1 mL of PBS buffer and incubated at 37°C. At predetermined time points, the supernatant was removed and replaced with fresh DMEM medium (containing 10% FBS and 2 mM glutamine). Subsequently, the AAV viral vector in the sample solution was quantified using real-time quantitative polymerase chain reaction (qPCR). The upstream and downstream primers used in the qPCR were as follows: upstream primer: 5'-ACCGCCGTTATGAAATCTTGCTT-3' (SEQ ID NO. 2), downstream primer: 5'-CCAGCAAACCTCCTCCAAGTCA-3' (SEQ ID NO. 3), using the WakoDNAExtractor SP kit.

[0083] The cumulative percentage of AAV viral vector release was estimated by dividing the AAV viral release amount determined by qPCR by the initial AAV viral load on the sample. The initial AAV viral load and release amount are shown in Table 2. In vitro release test results are as follows: Figure 4 As shown, PEO:PCL core-shell fiber represents the fiber-coated sample carrying recombinant virus vector in Example 1, and PEO:PCL ordinary fiber represents the fiber-coated sample carrying recombinant virus vector in Comparative Example 1.

[0084] Table 2. Cumulative release and initial loading of AAV viral vector in the fiber-coated samples carrying recombinant viral vectors in Example 1.

[0085]

[0086] Depend on Figure 4 It can be concluded that the initial burst release of the fiber membrane carrying the recombinant virus vector was 35%, which then turned into a stable and continuous release, with a cumulative release of 60% in 24 hours and 80% in 72 hours. In contrast, the cumulative release of the fiber membrane prepared in Comparative Example 1 remained at around 35%. This is due to the initial burst release and the significant reduction in AAV virus activity during the electrospinning preparation process.

[0087] Cell transduction assay: The fiber-coated samples prepared in Example 1 and Comparative Example 1 were incubated in DMEM medium (containing 10% FBS, 2 mM glutamine), and then 1 mL of cell culture medium suspension (containing 10% FBS, 2 mM glutamine) was added. 5 293 cells were seeded onto a fiber-coated membrane and cultured for 4 hours to allow cell attachment. The cells were then transferred to new culture wells and cultured for 3 days. The cell transduction efficiency was analyzed by flow cytometry.

[0088] The surface inoculation concentration of the fiber-coated sample prepared in Comparative Example 2 was 1×10⁻⁶. 5 Cells were cultured at 293 cells / mL in a 37°C incubator. At the predetermined time, the culture medium was aspirated, the cells were washed with PBS, and then 50 μL of lysis buffer was added. The cells were then tapped and collected for analysis. Finally, the fluorescence intensity of the fluorescent protein, i.e., the plasmid DNA transfection efficiency, was measured using a fluorescence spectrophotometer.

[0089] The cell transduction efficiency of AAV viral vector and the cell transfection results of plasmid DNA are as follows: Figure 5 As shown.

[0090] Depend on Figure 5 It can be concluded that the cell transduction efficiency of the fiber-coated membrane in Example 1 is 80%, which is significantly higher than that of Comparative Examples 1-2. Figure 5 It can be seen that the AAV viral vector used in this invention has a stronger cell transduction ability than the plasmid DNA vector used in Comparative Example 2. Moreover, the non-nuclear-shell nanofiber structure used in Comparative Example 1 shows a lower level of cell transfection efficiency compared to the core-shell nanofiber structure membrane used in this invention.

[0091] From the above examples, it can be concluded that the fiber coating of the recombinant viral vector prepared by the preparation method of the present invention can maintain the high activity of the loaded recombinant viral vector, enable the controllable release of gene drugs, and enable efficient transduction of host cells.

[0092] Although the above embodiments have provided a detailed description of the present invention, they are only some embodiments of the present invention, and not all embodiments. People can obtain other embodiments based on these embodiments without creative effort, and these embodiments all fall within the protection scope of the present invention.

Claims

1. A method for preparing a fiber-coated membrane carrying a recombinant viral vector, characterized in that, Includes the following steps: The inner spinning solution and the outer spinning solution are coaxially electrospun to obtain a coaxial electrospun core-shell fiber membrane. The inner spinning solution is a recombinant virus vector solution, and the outer spinning solution is a biodegradable polymer solution. The biodegradable polymer is polyethylene oxide and polycaprolactone, and the mass ratio of polyethylene oxide to polycaprolactone is 9:

1. The coaxial electrospun core-shell fiber membrane was freeze-dried to obtain the fiber membrane carrying the recombinant virus vector; The coaxial nozzle of the coaxial electrospinning includes an inner needle and an outer needle; the inner diameter of the inner needle is 0.15~0.55mm and the outer diameter is 0.6~0.8mm; the inner diameter of the outer needle is 0.85~1.3mm and the outer diameter is 1.25~1.75mm. The ratio of the spinning flow rate of the outer layer solution to that of the inner layer solution is 2:

1.

2. The preparation method according to claim 1, characterized in that, The biodegradable polymer solution comprises a biodegradable polymer and a first solvent, wherein the first solvent comprises at least one of chloroform, dichloromethane, and N,N-dimethylformamide; and the biodegradable polymer has a mass fraction of 5-20% in the biodegradable polymer solution.

3. The preparation method according to claim 1, characterized in that, The recombinant viral vector solution comprises a recombinant viral vector and a second solvent; the second solvent comprises at least one of phosphate buffer solution, chloroform, and dichloromethane. The initial viral vector of the recombinant viral vector includes an adeno-associated virus vector; the content of the recombinant viral vector in the recombinant viral vector solution is (1~3)×10 based on the number of particles of the initial viral vector. 9 Particles / μL.

4. The preparation method according to claim 1, characterized in that, The ambient temperature for coaxial electrospinning is 0~8℃; the relative humidity is 30~55%.

5. The preparation method according to claim 1, characterized in that, The voltage of the coaxial electrospinning is 9~22kV; the distance from the coaxial nozzle to the receiving device is 12~20cm; and the rotation speed of the receiving device is 500~700r / min.

6. The fiber-coated membrane carrying the recombinant viral vector prepared by the preparation method according to any one of claims 1 to 5, characterized in that, The fibers forming the fiber membrane carrying the recombinant viral vector have a core-shell structure, with the shell layer being a biodegradable polymer layer and the core layer being the recombinant viral vector; the thickness of the fiber membrane carrying the recombinant viral vector is 75~125μm, and the diameter of the fiber filaments is 0.3~1μm.

7. The use of the fiber coating of recombinant viral vector as described in claim 6 in the preparation of gene therapy devices.